BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19

• 

  Leadership

  The Four Employment Agreement Questions Every Pharma Executive Must Ask

  Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.

  December 18, 2025

   · 

  6 min read

   · 

  Michael Pietrack
• 

  Job Trends

  8 Companies Hiring in Greater Philadelphia

  If you’re looking for a biopharma job in Philadelphia, here are eight companies on BioSpace hiring right now.

  December 18, 2025

   · 

  1 min read

   · 

  Chantal Dresner
• 

  Collaboration

  GSK Makes $400M+ RNA Play With CAMP4 Collab, Targets Neuro, Kidney Diseases

  The Massachusetts biotech will also be eligible to milestone payments, though the exact amount has yet to be disclosed.

  December 18, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Regulatory

  FDA Mulls National Priority Vouchers for Two Potential Merck Blockbusters: Report

  The tickets could go to the lipid-lowering pill enlicitide decanoate and the antibody-drug conjugate sacituzumab tirumotecan, though a spokesperson for the HHS did not confirm the news.

  December 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Obesity

  Lilly’s Obesity Pill Maintains Weight Loss as Estimated Approval Timelines Inch Closer

  Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or Zepbound largely maintained their weight loss for up to a year.

  December 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  influenza

  Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine

  The money replaces a small portion of a contract Moderna lost when the Department of Health and Human Services canceled $760 million in backing to develop the vaccine, called mRNA-1018.

  December 18, 2025

   · 

  1 min read

   · 

  Dan Samorodnitsky
• 

  Obesity

  Novo Nordisk Files Combo Obesity Drug CagriSema For FDA Approval

  The filing comes as Novo fights tooth-and-nail with rival Lilly to regain its footing at the top of the weight loss market.

  December 18, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Layoffs

  Voyager Throws 30 Staff Overboard After Novartis Sinks Two Programs

  Novartis has discontinued two undisclosed programs under its current partership with Voyager, the biotech announced last month. Projects under the deal for spinal muscular atrophy and Huntington’s disease continue to advance.

  December 18, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Deals

  Inside the 2026 Biotech Landscape: Innovation, Investment and Global Momentum

  In this episode of Denatured, Jennifer Smith-Parker speaks to Kenneth Galbraith, ⁠CEO of Zymeworks and Josh Smiley, president and COO of Zai Lab, about how renewed confidence is driving biotech entering 2026.

  December 18, 2025

   · 

  1 min read

   · 

  BioSpace Insights
• Press Releases

  Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

  December 18, 2025

   · 

  14 min read